Opthea (ASX:OPT) completed its drug product process performance qualification campaign for its sozinibercept drug candidate to treat wet age-related macular degeneration, demonstrating its ability to consistently manufacture the candidate at a commercial scale, according to a Wednesday Australian bourse filing.
The campaign consisted of the production of three consecutive commercial-scale drug product batches.
This was required to further validate its manufacturing process in preparation for a potential biologics license application filing, as well as the commercialization of sozinibercept, in the first half of 2026.
The firm's shares fell 5% in early trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.